Loading...
•
Mar 31
Theravance Q1 2025 Earnings Report
Theravance Biopharma, Inc. reported its first quarter 2025 financial results, showing increased revenue and progress in key clinical trials.
Key Takeaways
Theravance Biopharma reported a total revenue of $15.4 million for Q1 2025, primarily from Viatris collaboration revenue. The company saw solid growth in YUPELRI net sales and continued progress in the CYPRESS study for ampreloxetine, with enrollment nearing completion.
YUPELRI® (revefenacin) net sales, recognized by Viatris, increased 6% to $58.3 million in Q1 2025 compared to Q1 2024.
TRELEGY net sales, as reported by GSK, increased 14% to $854 million in Q1 2025 compared to Q1 2024.
CYPRESS study open label enrollment for ampreloxetine is nearing completion, with top-line data anticipated ~6 months after final patient enrollment.
The company's quarter-end cash balance was $131 million, with no debt, and all financial guidance metrics were reaffirmed.
Theravance
Theravance
Theravance Revenue by Segment
Revenue by Segment
YUPELRI Collaboration Revenue
CapyFin.com Forward Guidance
Theravance Biopharma reaffirmed its full-year 2025 financial guidance, expecting operating expenses (excluding share-based compensation) and share-based compensation expenses to remain within specified ranges, and Non-GAAP Losses from Operations and Cash Burn to be similar to 2024 levels.
Positive Outlook
- Full year 2025 R&D expenses (excluding share-based compensation) are expected to be between $32 million and $38 million.
- Full year 2025 SG&A expenses (excluding share-based compensation) are expected to be between $50 million and $60 million.
- Full year 2025 share-based compensation expenses are expected to be between $18 million and $20 million.
- 2025 Non-GAAP Losses from Operations are expected to be similar to levels incurred in 2024.
- 2025 Cash Burn is expected to be similar to levels incurred in 2024.
Challenges Ahead
- No specific negative forward guidance points were provided in the report; the company reaffirmed its existing guidance.